Lisaftoclax
A Bcl-2 inhibitor used in cancer treatment
| Lisaftoclax | |
|---|---|
| |
| INN | |
| Drug class | |
| Routes of administration | |
| Pregnancy category | |
| Bioavailability | |
| Metabolism | |
| Elimination half-life | |
| Excretion | |
| Legal status | |
| CAS Number | |
| PubChem | |
| DrugBank | |
| ChemSpider | |
| KEGG | |
Lisaftoclax is a small molecule Bcl-2 inhibitor that is being investigated for its potential use in the treatment of various types of cancer. It is designed to induce apoptosis in cancer cells by inhibiting the Bcl-2 protein, which is often overexpressed in cancerous cells and contributes to their survival.
Mechanism of Action[edit]
Lisaftoclax functions by targeting the Bcl-2 protein, a member of the Bcl-2 family of proteins that regulate cell death (apoptosis). Bcl-2 is an anti-apoptotic protein that helps cancer cells evade the normal process of programmed cell death, allowing them to survive and proliferate. By inhibiting Bcl-2, lisaftoclax promotes apoptosis in cancer cells, thereby reducing tumor growth.
Development and Clinical Trials[edit]
Lisaftoclax is currently undergoing clinical trials to evaluate its safety and efficacy in humans. These trials are crucial for determining the appropriate dosing, potential side effects, and therapeutic benefits of the drug. The development of lisaftoclax is part of a broader effort to create targeted therapies that specifically attack cancer cells while minimizing damage to normal cells.
Potential Applications[edit]
Lisaftoclax is being studied for its potential use in treating several types of cancer, including chronic lymphocytic leukemia (CLL), non-Hodgkin lymphoma, and other hematological malignancies. Its ability to specifically target the Bcl-2 protein makes it a promising candidate for combination therapies, where it can be used alongside other treatments to enhance overall efficacy.
Challenges and Considerations[edit]
While lisaftoclax shows promise, there are challenges associated with its development and use. These include managing potential side effects, such as tumor lysis syndrome, which can occur when a large number of cancer cells die rapidly. Additionally, researchers are investigating the potential for resistance to lisaftoclax, which could limit its long-term effectiveness.
Related pages[edit]
Ad. Transform your life with W8MD's
GLP-1 weight loss injections special from $29.99 with insurance
|
WikiMD Medical Encyclopedia |
Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
